Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients


Alector Inc ALEC detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021)

  • Patients with one type of frontotemporal dementia decline because they're missing one copy of an immune-regulating gene called progranulin and subsequently have half the amount of the protein healthy adults have. 
  • In 9 patients, Alector showed that their antibody, AL001, brought progranulin levels back to near-normal levels after a half-year. Seven stayed at near-normal after a year.
  • The Company also showed that most of those patients improved across a range of biological correlates for cognitive function, including the rate at which patients' brains shrunk. Data also claimed the treatment slowed patients' mental decline. 
  • Although investigators didn't have a control arm, they matched subjects with similar patients from a medical database and said those who received treatment declined 47% more slowly.
  • Last year, the Company launched a Phase 3 trial that will enroll 180 patients and randomize them to receive either AL001 or placebo for 96 weeks.
  • Earlier this month, GlaxoSmithKline plc GSK gave Alector $700 million cash and $1.5 billion in milestones to co-develop AL001 and AL101.
  • Price Action: ALEC shares are down 8.5% at $27.92 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsShort IdeasHealth CareContractsMoversTrading IdeasGeneralBriefsdementiaPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!